SEC Form 4 · accession 0001127602-15-012590
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairman & Co-CEO · Director
Period of report
Mar 25, 2015
Accepted (ET)
Mar 26, 2015 · 8:58 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 25, 2015 | M | 2,211 | $63.22 | A | 2,451 | D | |
| Common StockF2 | Mar 25, 2015 | S | 411 | $169.7268 | D | 2,040 | D | |
| Common StockF3 | Mar 25, 2015 | S | 200 | $172.105 | D | 1,840 | D | |
| Common StockF4 | Mar 25, 2015 | S | 800 | $173.4775 | D | 1,040 | D | |
| Common StockF5 | Mar 25, 2015 | S | 300 | $175.2267 | D | 740 | D | |
| Common StockF6 | Mar 25, 2015 | S | 300 | $176.30 | D | 440 | D | |
| Common StockF7 | Mar 25, 2015 | S | 200 | $177.775 | D | 240 | D | |
| Common Stock | holding | — | — | — | 166 | I | By Spouse | |
| Common Stock | holding | — | — | — | 533,094 | I | By Trusts |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options | $63.22 | Mar 25, 2015 | M | 2,211 | D | Dec 31, 2010 | Dec 31, 2020 | Common Stock | 2,211 | 435,586 | D |
Explanation of responses
- F1This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
- F2This transaction was executed in multiple trades at prices ranging from $169.72 to $169.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $171.66 to $172.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $173.15 to $173.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $174.46 to $175.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $176.02 to $176.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $177.65 to $177.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.